Correlations of disease severity outcome measures in inclusion body myositis

Published:August 23, 2022DOI:


      • IBMFRS strongly correlated to Rankin, MMT12, and timed get up (|r| =0.78-0.81).
      • IBMFRS modestly correlated to mOBFRS, FVC and grip/pinch (r = 0.41-0.66).
      • Timed get up strongly correlated with MMT12 (r = -0.76).
      • Several IBM outcome measures showed significant correlations with one another.


      This study aimed to evaluate the correlation between various outcome measures used to assess disease severity and progression in inclusion body myositis (IBM) clinical trials. A cross-sectional study, involving 51 IBM patients meeting the European Neuromuscular Center (ENMC) 2011 criteria for clinically defined or probable IBM, was completed at the University of California, Irvine. Clinical details, demographic data, and functional data including timed get up (TGU), manual muscle testing, hand grip, pinch dynamometry, as well as IBM functional rating scale (IBMFRS), modified Rankin score, forced vital capacity (FVC), and modified ocular bulbar facial respiratory scale (mOBFRS) were collected on all patients. Descriptive statistics and Pearson's r correlation were performed to analyze the data. Age of the patient did not correlate with any of the outcome measures. Greater severity of IBMFRS scores correlated with longer disease duration as well as greater severity for FVC, strength outcomes, TGU, modified Rankin, and mOBFRS. Additionally, TGU strongly correlated with muscle strength measurements, modified Rankin, and mOBFRS. mOBFRS moderately correlated with IBMFRS, muscle strength, FVC, TGU and modified Rankin score. We demonstrate moderate to strong correlations among the disease severity outcome measures in this study.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Neuromuscular Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Weihl CC.
        Sporadic inclusion body myositis and other rimmed vacuolar myopathies.
        Continuum. 2019; 25 (Minneapolis, Minn): 1586-1598
        • Weihl CC
        • Mammen AL.
        Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy.
        Neuropathol Appl Neurobiol. 2017; 43: 82-91
        • Pestronk A.
        Acquired immune and inflammatory myopathies: pathologic classification.
        Curr Opin Rheumatol. 2011; 23: 595-604
        • Schmidt K
        • Schmidt J.
        Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.
        Curr Opin Rheumatol. 2017; 29: 632-638
        • Benveniste O
        • Hogrel JY
        • Annoussamy M
        • Bachasson D
        • Rigolet A
        • Servais L.
        Rapamycin vs. placebo for the treatment of inclusion body myositis: improvement of the 6 min walking distance, a functional scale, the FVC and muscle quantitative MRI [abstract].
        Arthritis Rheumatol. 2017; 69 (Suppl): 5L
        • Jackson CE
        • Barohn RJ
        • Gronseth G
        • Pandya S
        • Herbelin L
        • Group M.
        Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.
        Muscle Nerve. 2008; 37: 473-476
        • Allenbach Y
        • Benveniste O
        • Decostre V
        • Canal A
        • Eymard B
        • Herson S
        • et al.
        Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis.
        Neuromuscular Disord. 2012; 22: 980-986
        • Cortese A
        • Machado P
        • Morrow J
        • Dewar L
        • Hiscock A
        • Miller A
        • et al.
        Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.
        Neuromuscular Disord. 2013; 23: 404-412
        • Hogrel JYY
        • Allenbach Y
        • Canal A
        • Leroux G
        • Ollivier G
        • Mariampillai K
        • et al.
        Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials.
        Neuromuscular Disord. 2014; 24: 604-610
        • Sangha G
        • Yao B
        • Lunn D
        • Skorupinska I
        • Germain L
        • Kozyra D
        • et al.
        Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis.
        J Neurol Neurosurg Psychiatry. 2021; (Apr 13:jnnp-2020-325141)
        • Goyal NA
        • Coulis G
        • Duarte J
        • Farahat PK
        • Mannaa AH
        • Cauchii J
        • et al.
        Immunophenotyping of inclusion body myositis blood T and NK cells.
        Neurology. 2022; 98 (Mar 29): e1374-e1383
        • Kendall FP ME
        • Provance PG
        Muscles: Testing and Function.
        fourth ed. Williams and Wilkins, Baltimore1993
        • Farrugia ME
        • Harle HD
        • Carmichael C
        • Burns TM.
        The Oculobulbar Facial Respiratory score is a tool to assess bulbar function in myasthenia gravis patients.
        Muscle Nerve. 2011; 43: 329-334
        • Chan YH.
        Biostatistics 104: correlational analysis.
        Singapore Med J. 2003; 44: 614-619
        • Hanna MG
        • Badrising UA
        • Benveniste O
        • Lloyd TE
        • Needham M
        • Chinoy H
        • et al.
        Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
        Lancet Neurol. 2019; 18: 834-844
        • Morrow JM
        • Sinclair CD
        • Fischmann A
        • Machado PM
        • Reilly MM
        • Yousry TA
        • et al.
        MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.
        Lancet Neurol. 2016; 15: 65-77
        • Hogrel JYY.
        Still seeking the holy grail of outcome measures in inclusion body myositis.
        J Neurol Neurosurg Psychiatry. 2021; (Apr 13:jnnp-2021-326460)
        • Oldroyd AGS
        • Lilleker JB
        • Williams J
        • Chinoy H
        • Miller JAL.
        Long-term strength and functional status in inclusion body myositis and identification of trajectory subgroups.
        Muscle Nerve. 2020; 62: 76-82